Moderna soars 24% after the drug maker posts upbeat results from cancer vaccine trial

Dec 13 2022 by Business Insider

 
Stephane Bancel, CEO of Moderna

Nancy Lane/MediaNews Group/Boston Herald

Moderna stock jumped more than 24% Tuesday on upbeat results from a cancer treatment trial. The company reported its cancer vaccine combined with Keytruda reduced patients' risk by about 44%. Shares of Moderna are trading around $207, and remain down about 13.5% year-to-date.

Shares of Moderna jumped more than 24% on Tuesday after the company announced promising results from a cancer treatment trial in combination with...

Continue Reading Moderna soars 24% after the drug maker posts upbeat results from cancer vaccine trial